Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?

EPMA Journal

Johann S de Bono¹  Charles Swanton²  Timothy A Yap¹ 

[1] Division of Clinical Studies, The Institute of Cancer Research, 15 Cotswold Rd, Sutton, Surrey SM2 5NG, UK;Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, 44 Lincoln's Inn Fields, London WC2A 3PX, UK

关键词: Personalized treatment;    Targeted prevention;    Predictive diagnostics;    Novel clinical trial designs;    Intermediate endpoint biomarkers;    Prostate cancer;   

Others  :  802168
DOI  :  10.1007/s13167-011-0138-2

 received in 2011-11-28, accepted in 2011-12-21,  发布年份 2012

【 摘 要 】

Prostate cancer remains the most common malignancy among men and the second leading cause of male cancer-related mortality. Death from this disease is invariably due to resistance to androgen deprivation therapy. Our improved understanding of the biology of prostate cancer has heralded a new era in molecular anticancer drug development, with multiple novel anticancer drugs for castration resistant prostate cancer now entering the clinic. These include the taxane cabazitaxel, the vaccine sipuleucel-T, the CYP17 inhibitor abiraterone, the novel androgen receptor antagonist MDV-3100 and the radionuclide alpharadin. The management and therapeutic landscape of prostate cancer has now been transformed with this growing armamentarium of effective antitumor agents. This review discusses strategies for the prevention and personalization of prostate cancer therapy, with a focus on the development of predictive and intermediate endpoint biomarkers, as well as novel clinical trial designs that will be crucial for the optimal development of such anticancer therapeutics.

【 授权许可】

   
2012 Yap et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
• [2]Attard G, Sarker D, Reid A, Molife R, Parker C, de Bono JS: Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. Br J Cancer 2006, 95:767-74.
• [3]Yap TA, Zivi A, Omlin A, de Bono JS: The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 2011, 8:597-610.
• [4]de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al.: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-54.
• [5]Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al.: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-22.
• [6]de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al.: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011, 364:1995-2005.
• [7]Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al.: Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010, 375:1437-46.
• [8]Albertsen PC: When is active surveillance the appropriate treatment for prostate cancer? Acta Oncol 2011, 50(Suppl 1):120-6.
• [9]Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al.: Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004, 350:2239-46.
• [10]Andriole GL, Crawford ED, Grubb RL, Buys SS, Chia D, Church TR, et al.: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009, 360:1310-9.
• [11]Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al.: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009, 360:1320-8.
• [12][http://www.uspreventiveservicestaskforce.org/draftrec3.htm] webcite Screening for prostate cancer: draft recommendation statement Rockville, MD: US Preventive Services Task Force, October 7, 2011
• [13]Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, et al.: Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009, 69:2912-8.
• [14]Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, Chen Y, et al.: Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005, 24:3847-52.
• [15]Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al.: Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-8.
• [16]Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, et al.: Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008, 27:253-63.
• [17]Narod SA, Seth A, Nam R: Fusion in the ETS gene family and prostate cancer. Br J Cancer 2008, 99:847-51.
• [18]Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al.: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-12.
• [19]Collette L, Burzykowski T, Carroll KJ, Newling D, Morris T, Schroder FH: Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. J Clin Oncol 2005, 23:6139-48.
• [20]Baker SG: Surrogate endpoints: wishful thinking or reality? J Natl Cancer Inst 2006, 98:502-3.
• [21]Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, et al.: Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008, 26:1148-59.
• [22]Biomarkers Definitions Working Group Bethesda M: Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
• [23][http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ucm120857.pdf] webcite
• [24]Attard G, de Bono JS: Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin Cancer Res 2011, 17:3867-75.
• [25]Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al.: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-91.
• [26]de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al.: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008, 14:6302-9.
• [27]Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al.: Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:3213-21.
• [28]Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al.: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004, 10:6897-904.
• [29]Attard G, de Bono JS: Utilizing circulating tumor cells: challenges and pitfalls. Curr Opin Genet Dev 2010, 21:50-8.
• [30]Olmos D, Arkenau HT, Ang JE, Ledaki I, Attard G, Carden CP, et al.: Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 2009, 20:27-33.
• [31]Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, et al.: Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009, 10:233-9.
• [32]Scher HI, Heller G, Molina A, Kheoh TS, Attard G, Moreira J, et al.: Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): Planned final analysis (FA) of COU-AA-301, a randomized double-blind, placebo-controlled phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J Clin Oncol 2011, 29:Abstr LBA4517.
• [33]Kim ES, Herbst RS, Lee JJ, Blumenschein GR Jr, Tsao A, Alden CM, et al.: The BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination): personalizing therapy for lung cancer. In Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21. Washington, DC Philadelphia (PA): AACR; 2010:Abstr LB-1.
• [34][http://www.clinicaltrials.gov] webcite